DocMorris

Jefferies raised the target price for DocMorris from 9.50 to 11.00 francs but cut its rating from Buy to Hold. Analyst Martin Comtesse said the downgrade was due to improved growth and margin prospects already being largely priced in. The DocMorris share briefly fell about 2 percent on the SIX. Jefferies named Redcare as its new favourite among online pharmacies. » More on finanzen.net

DocMorris reported surprisingly strong Q2 figures with currency-adjusted external revenue up 15.2% and Rx growth of 45.8%. Adjusted EBITDA improved markedly in the half-year from −28.8 to −10.9 million CHF, and the EBITDA margin also improved; however, cash declined to around CHF 99.2 million. Management raised its revenue and EBITDA ranges for 2026 and expects strong Rx and digital services growth; the goal remains half-year EBITDA breakeven in H2 and free-cash-flow breakeven in 2027. Analysts have revised price targets upward, bringing the stock back within reach of the year high. » More on finanzen.net

Deutsche Bank Research has raised the price target for DocMorris from 11.5 to 12.5 francs and confirmed the rating at "Buy." Analyst Jan Koch sees the turnaround story as more credible after a roadshow and a presentation of the figures. The DocMorris share at one point fell 0.75 percent and was trading at 9.88 francs on the SIX. » More on finanzen.net